Quick Answer
Co-Diagnostics, Inc. reported Gross Profit of $400.1 thousand for the year ending 2025.
- Co-Diagnostics, Inc. showed a decrease of -86.3% in Gross Profit from 2024 to 2025.
- This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $2.2 thousand | Q3 2017: $2.6 thousand | Q1 2018: $9.7 thousand | Q2 2018: $9.7 thousand | Q3 2018: $9.7 thousand | Q1 2019: $2.9 thousand | Q2 2019: $22.8 thousand | Q3 2019: $21.1 thousand | Q1 2020: $1.07 million | Q2 2020: $18.06 million | Q3 2020: $16.00 million | Q1 2021: $16.75 million | Q2 2021: $24.85 million | Q3 2021: $26.79 million | Q1 2022: $19.42 million | Q2 2022: $4.11 million | Q3 2022: $4.33 million | Q1 2023: $99.7 thousand | Q2 2023: -$261.3 thousand | Q3 2023: $2.20 million | Q1 2024: $233.3 thousand | Q2 2024: $2.44 million | Q3 2024: $343.7 thousand | Q1 2025: $28.7 thousand | Q2 2025: $130.8 thousand | Q3 2025: $119.1 thousand.
- Over the full 9 years of available data (2017 to 2025), Co-Diagnostics, Inc.'s Gross Profit has grown by 5,336.3%.
- Historical annual values: Fiscal year 2025: $400.1 thousand | Fiscal year 2024: $2.92 million | Fiscal year 2023: $2.63 million | Fiscal year 2022: $28.74 million | Fiscal year 2021: $86.31 million | Fiscal year 2020: $57.96 million | Fiscal year 2019: $102.5 thousand | Fiscal year 2018: $30.5 thousand | Fiscal year 2017: $7.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: